
CLAIMS

1. A compound comprising formula II:




II


wherein,


R^1 denotes COOH, COOA, COA, cyano, or if n of $(R_4)_n$ is 4, R^1 also denotes $CON(R^3)_2$ or CONHA;

R^2 denotes H, Hal, A or O-A;

R^a is selected from the group consisting of







X^1 , X^2 denote each independently of one another NR^c or NR^d; provided that one of X^1 and X^2 is NR^c;

R^b and R^c together represent a chemical bond;

R^d denotes H or A;

with a proviso that when R^a is  , R^1 is -COOH, and n is 0, then R_2 is not Hydrogen;

Hal denotes F, CI, Br or I;

A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by OR^3 and wherein one or more, preferably 1 to 7 non-adjacent CH_2-groups may be replaced by O, or S and/or by -CH=CH- or -C=C- groups, or denotes cycloalkyl having 3-7 ring C atoms;

R^3 is H or alkyl;

















R^4 is halo or alkoxy;

















R^5 at each occurrence is independently selected from Hal, hydroxy, alkoxy, carboxy, perfluoro-alkyl, perfluoro-alkyloxy, cyano, nitro, amino, amido, or alkyl;









n denotes 0,1, 2, 3 or 4;









and pharmaceutically acceptable solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.









2. A compound selected from the group consisting of:









	I2		I13
	I3		I14
	I4		I15
	I5		I16
	I6		I17
	I10		I18
	I11		I20
	I12		I21

















	I22
	I23
	I24
	I25
	I26
	I27
	I28
	I29
	I30
	I31
	I32
	I33
	I34
	I35
	I38
	I41

















	144
	145
	146
	147
	148
	152
	154
	155

















	156
	157
	158
	159
	160
	162
	165
	166

















	167
	168
	170
	171
	172
	173
	174
	176

















	177
	178
	182
	183
	185
	186
	187
	188









	I89
	I90
	I91
	I93
	I94
	I95
	I96
	I97
	I98
	I99
	I100
	I101
	I102
	I104
	I105
	I106

	I107
	I109
	I110
	I112
	I113
	I114
	I115
	I116
	I117
	I118
	I119
	I120
	I121
	I123
	I124
	I125

	I126
	I127
	I128
	I129
	I130
	I131
	I132
	I133
	I134
	I136
	I137
	I139
	I140
	I141
	I143
	I144

	I145
	I146
	I147
	I148
	I149
	I150
	I151
	I152
	I153
	I154
	I155
	I156
	I157
	I158
	I160
	I161

	I162
	I163
	I164
	I167
	I168
	I169
	I170
	I171
	I172
	I173
	I175
	I176
	I177
	I178
	I179
	I182

	I183		I188
	I184		I189
	I185		I190
	I186		I192

and pharmaceutically acceptable solvates, tautomers, salts and stereoisomers thereof including mixtures thereof in all ratios.

3. A pharmaceutical composition comprising at least one compound according to claim 1 and/or pharmaceutically acceptable tautomers, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

4. A pharmaceutical composition comprising at least one compound according to claim 1 and/or pharmaceutically acceptable tautomers, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further active ingredient.

5. Use of compounds according to claim 1, and pharmaceutically acceptable salts, tautomers, solvates and stereoisomers thereof including mixtures thereof in ail ratios, in the preparation of a medicament for the treatment of a dihydroorotate dehydrogenase associated disorder; wherein the dihydroorotate dehydrogenase associated disorder is an autoimmune disorder or condition associated with an overactive immune response.


6. Use of compounds according to claim 1, and pharmaceutically acceptable salts, tautomers, solvates and stereoisomers thereof, including mixtures thereof in all ratios, in the preparation of a medicament for the treatment of an immunoregulatory abnormality; wherein the immunoregulatory abnormality is selected from the group consisting of amyotrophic lateral sclerosis (ALS), systemic lupus erythematosus, rheumatoid arthritis, type I diabetes mellitus, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis, Crohn's disease, ulcerative colitis, bullous pemphigoid, sarcoidosis, psoriasis, autoimmune myositis, Wegener's granulomatosis, ichthyosis, Graves ophthalmopathy, asthma, bone marrow or organ transplant rejection, and graft-versus-host disease.

7. The use according to claim 6, wherein the immunoregulatory abnormality is multiple sclerosis or rheumatoid arthritis.

8. Use of the compounds, and pharmaceutically acceptable salts, tautomers, solvates and stereoisomers thereof including mixtures thereof in all ratios, according to claim 1 in the preparation of a medicament for the treatment of cancer diseases.

9. A process for the preparation of compounds of Formula (II) wherein X^1 and X^2 are NR^c or NR^d and wherein R^b and R^c together represent a chemical bond, characterized in that:


Compound (A)



(A)

wherein R^1, R^2 are as defined in claim 1,

is reacted with compound (B)



(B)

wherein R_4, n and R^a are as defined in claim 1.